ENTA—Thanks for those projections. For the US+EU patient pool, I modeled 55% EU and 45% US because the EU market is considerably larger than just the "Big-5" EU countries (Germany, France, UK, Italy, Spain) referenced in your post.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”